Jason Pogue, PharmD, BCPS-ID, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.
Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains the clinical significance of his research team’s findings regarding the use of ceftolozane-tazobactam to treat Pseudomonas infections.
Interview Transcript (slightly modified for readability)
“The clinical significance of the results of our study is it just demonstrates that [using ceftolozane-tazobactam to treat Pseudomonas patients] is a potential excellent option for us. Even when our traditional beta-lactam alternatives fail, this can help us to avoid more toxic suboptimal therapies in those patients. And so, while are data are limited by the fact that we didn’t look at outcomes, we don’t know what they were treated with or what they did, they clearly show that this is an alternative therapy that clinicians can think about in these patients, and hopefully be able to give a first-line therapeutic option.”
DISCLOSURES: Jason Pogue is a Consultant for Merck, Allergan, Med Co, Shionogi, Zavante, Achaogen. This study was supported by a grant from Merck.